90%Confidence
0Views
FDASource
2026-03-06Date
Summary
Fresenius Kabi's ketamine product faces sterility concerns, potentially affecting psychiatric and pain management treatments. This recall highlights systemic quality issues across multiple compounded products from the same facility.
Actionable: Investigate Fresenius Kabi's entire compounding product line for similar sterility issues.
AI Confidence: 90%
Data Points
firmFresenius Kabi Compounding, LLC
classificationClass II
statusOngoing
distributionUS Nationwide.
productketamine HCl, 1,000 mg, 1,000 mg per 100 mL (10 mg per mL) in Sodium Chloride Injection, Fagron Sterile Services, 20 Dan Road, Canton, MA 02021, NDC 7
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now